On Feb. 17, 2017, the U.S. total market cap / gross domestic product ratio reached 130%, a critical milestone as valuations remain significantly overvalued. Most of Warren Buffett (Trades, Portfolio)’s portfolio holdings as of Dec. 31, 2016, have price-sales valuations greater than the 80th percentile of the industry. Such companies include The Coca-Cola Co. (NYSE:KO), International Business Machines Corp. (NYSE:IBM), Delta Air Lines Inc. (NYSE:DAL), Apple Inc. (NASDAQ:AAPL) and Southwest Airlines Co. (NYSE:LUV).
Buffett indicator reaches critical milestone
Buffett pointed out that the ratio of the Wilshire 5000 full-cap index over the gross domestic product is “probably the best single measure of where valuations stand at any given moment.” The total market index is currently $24513.4 billion, about 130% of the last reported U.S. GDP. Such market valuations seldom appeared since the dot-com bubble of 2000, when the Buffett indicator reached nearly 150%. Figure 1 shows the historical trendline of the Buffett indicator since 1970.
Top 10 Warren Buffett Stocks To Invest In 2018: Fresh Del Monte Produce, Inc.(FDP)
- [By Lee Jackson]
The man at the top of Fresh Del Monte Produce Inc. (NYSE: FDP) wasselling stock last week. Chairman and CEO Mohammad Abu-Ghazaleh shed a block of 50,000 shares at prices that ranged from $57.85 to $58.46 apiece. The total was listed at $2.9 million. The stock ended the weekat $58.31, in a 52-week range of $41.70 to $66.86. The consensus price target is $70.30.
- [By John Udovich]
Thanksgiving is almost here and aside from featuring a turkey, most Thanksgiving dinners will include items from a range of consumer stocks including Campbell Soup Company (NYSE: CPB), Kraft Heinz Co (NASDAQ: KHC), Fresh Del Monte Produce Inc (NYSE: FDP) and McCormick & Company (NYSE: MKC) along with aThanksgiving turkey from Hormel Foods Corporation (NYSE: HRL)or Seaboard Corporation (NYSEAMEX: SEB). According tothe American Farm Bureau Federation,a classic Thanksgiving dinner will cost$49.87 for a gathering of 10 orjust under $5 per person down from 2015s all-time high of $50.11.
Top 10 Warren Buffett Stocks To Invest In 2018: Orbital ATK, Inc.(OA)
- [By Rich Smith]
While Trump’s nuclear tweet appears to have taken some folks off guard, the fact is that the U.S. has been planning a major upgrade and refurbishmentof its nuclear arsenal for quite some time — since at least the early years of the second Obama administration, in fact. As far back as three years ago, we were writing about a U.S. Air Force effort to begin upgrading the nation’s aging fleet of Minuteman III intercontinental ballistic missiles — a contract that Aerojet Rocketdyne (NYSE:AJRD), among others, is counting on to juice its rocket revenues. Rival rocket scientist Orbital ATK (NYSE:OA) is bidding on the same contract, and whether it’s Aerojet or Orbital that eventually ends up winning this piece of the nuclear rearmament project, there should be money aplenty to go around.
- [By Rich Smith]
Orbital ATK (NYSE:OA) occupies a charmed space in the U.S. market for putting satellites in, er, space.
At one end of the space launch continuum, you have United Launch Alliance, whose Delta IV Heavy launch vehicle, developed by Boeing (NYSE:BA), can put a payload massing in excess of 28 tonsinto orbit in a single launch — at a cost of $350 million.At the other end, new space start-ups like Vector Space are promising to launch a new generation of small satellites into low-earth orbit for prices as little as $2 million a shot. But what about the middle?
- [By Rich Smith]
Now consider that as of the last report, Americans owned 265 million guns — but fewer than 1 million silencers. That’s a huge market that American Outdoor Brands and Sturm, Ruger would love to sell into. Easing restrictions on silencer sales could have follow-on effects, too. Granting easier access to suppressors could reduce noise complaints at open-air shooting ranges, making it easier for such businesses to open, which would attract more customers, resulting in more ammunition being used, resulting in more ammunition being sold, resulting in more sales (and profits) for ammo makers such as Olin Corp (NYSE:OLN), Vista Outdoor (NYSE:VSTO), and Orbital ATK (NYSE:OA).
- [By Lisa Levin]
Defense giant Northrop Grumman Corporation (NYSE: NOC) confirmed Monday it will buy Orbital ATK Inc (NYSE: OA), the maker of the Pegasus rocket and a vast array of other aerospace and defense systems, in a $9.2 billion deal.
- [By Jim Robertson]
Last Monday, U.S. defense contractor Northrop Grumman Corporation (NYSE: NOC) announced it would buy Orbital ATK Inc (NYSE: OA), a direct Aerojet Rocketdyne competitor,for about $7.8 billion (a 22% premium to Orbital’s Friday close) in a deal thatwill give it greater access to lucrative government contracts and expand its arsenal of missile defense systems and space rockets. While Northrop already has a significant presence in payloads, it has not had launcher capability, an area that Orbital brings for both space and missile defense. Orbital also has contracts with NASA and the U.S. Army. The all-cash transaction is the biggest in the defense sector in two years and comes ahead of planned upgrades of U.S. ballistic systems (as the saber rattling by North Korea continues), which are expected to drive demand for missiles.
Top 10 Warren Buffett Stocks To Invest In 2018: Alnylam Pharmaceuticals Inc.(ALNY)
- [By Brian Orelli]
Alnylam Pharmaceuticals (NASDAQ:ALNY) jumped as much as 14.5% today after announcing earnings after the bell yesterday. As a development-stage biotech, it wasn’t the revenue or the earnings that caused the spike, but the progression of Allnylam’s pipeline.
- [By Cory Renauer]
Treating diseases that have a genetic component by altering the expression of the responsible genes is a promising new field of medicine, but it has been much less straightforward than biopharmaceutical companies had expected. Two contenders in this area, Alnylam Pharmaceuticals (NASDAQ:ALNY) and Ionis Pharmaceuticals (NASDAQ:IONS), saw a mix of setbacks and success in 2016.
- [By Chris Dier-Scalise]
On Thursday, the Vetr crowd downgraded Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) from 4.5 stars (Strong Buy), which was issued two days ago, to 3.5 stars (Hold). Crowd sentiment for Alnylam at the time of the downgrade was edging positive, with 66 percent of Vetr user rating bullish.
- [By Ben Levisohn]
Yesterday, after markets closed, it was announced that US Federal District Court Judge Sue Robinson ruled to issue a permanent injunction against Praluent, the PCSK9 mAb for hypercholesterolemia from partners Regeneron and Sanofi, due to infringement of patents from Amgen. The court has imposed a 30-day suspension (stay) on the injunction to allow for settlement or appeal of the District Court decision. Sanofi and Regeneron have announced their intent to appeal the ruling to the US Court of Appeals for the Federal Circuit (CAFC). The injunction decision is consistent with our counter-consensus published views communicated on 25 January 2016 (“Downgrade to Sell on evidence of likely infringement of Amgen’s PCSK9 patents”) and subsequently. Based on consultation with expert legal counsel, we now put >75% probability Amgen will prevail on appeal and/or Praluent is ultimately removed from the US market, and/or Amgen achieves a settlement substantially in its favor. We currently model $3.3 bn in non-risk-adjusted 2022E US revenues for Praluent, while consensus models $1.2 bn in 2022E US revenues. We reiterate our view from 25 January 2016 to preferentially own Amgen, The Medicines Company (MDCO) (Buy), and Alnylam (ALNY) (Buy) over Regeneron for exposure to PCSK9 inhibitor market dynamics as outcomes trials approach.
- [By Lisa Levin]
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) shares shot up 53 percent to $114.87 after the company impressed investors with encouraging data from a phase 3 clinical trial. Alnylam, a company dedicated towards treating a wide range of debilitating diseases through ribonucleic acid (RNA) interference (RNAi) therapeutics, said after Tuesday's market close that a phase 3 study called APOLLO met its primary efficacy endpoint and all secondary endpoints.
Top 10 Warren Buffett Stocks To Invest In 2018: Jazz Pharmaceuticals Inc.(JAZZ)
- [By Jim Robertson]
The earnings report summarized the following recent milestones:
The formation of a Scientific Advisory Board (SAB) to provide expert guidance and insight as the Company advances towards product commercialization. in October, Pfenex announced the hiring of Steven Sandoval as Chief Manufacturing Officer.Steven has over 25 years of commercial biopharmaceutical engineering and operations experience, specializing in commercial operations, facility design and licensure of large scale biopharmaceutical commercial manufacturing facilities. Following the announcement in August of the positive Phase 1 trial data for Pfenex’s recombinant anthrax vaccine, discussions with BARDA have been progressing. Pfenex anticipates initiating the PF708 pivotal clinical program by year end. Pfenex entered into a collaboration with Jazz Pharmaceuticals plc (NASDAQ: JAZZ) on multiple hematology/oncology product candidates in July. Regulatory feedback for PF529, Pfenex’s biosimilar candidate to Neulasta (pegfilgrastim), is expected by the end of 2016 and following that feedback, the development path and potential timeline will be outlined.
Do you like this trading idea and want more trading setups delivered to you every day? Consider investing in a subscription to our SmallCap Network Elite Opportunity (SCN EO) portfolio newsletter or our Under the Radar Movers newsletter where you’ll get more and even better trading setups, investing ideas or tips.
- [By Keith Speights]
In December, I included Jazz Pharmaceuticals (NASDAQ:JAZZ) in a list of the three top healthcare stocks investors were overlooking. At that time, I noted that the biotech stock could be a diamond in the rough with its promising pipeline and low valuation.
- [By Teresa Rivas]
Jazz Pharmaceuticals (JAZZ) is trading up nearly 9% Thursday, thanks to its settlement with Hikma Pharmaceuticals over the firms patent dispute.
As part of the agreement, Hikma will get to sell a generic version of the drug in question, narcolepsy treatment Xyrem, in 2023, for up to five years, while Jazz will get royalties on those sales.
Janney Montgomery Scotts Ken Trbovich upgraded the shares from Neutral to Buy on the news, and also increased his price target from $138 to $175. From his note:
While this comes about three years earlier than previous settlements with other generic filers, it eliminates the risk of an earlier launch. Six months thereafter Hikma may launch its own generic and others may potentially be able to launch as well. Importantly, Jazz will receive a meaningful royalty on sales, retain the right to launch its own AG, and can authorize other AGs after the initial 6-month Hikma period.
Jazz shares are up 8.9% to $153.2o at recent check.
- [By Lisa Levin] Gainers
Trevena Inc (NASDAQ: TRVN) rose 10.8 percent to $3.60 in pre-market trading after dropping 4.97 percent on Wednesday.
Yum China Holdings Inc (NYSE: YUMC) rose 10.2 percent to $31.05 in pre-market trading after the company reported upbeat earnings for its first quarter.
Seres Therapeutics Inc (NASDAQ: MCRB) rose 9.1 percent to $11.39 in pre-market trading after dropping 5.26 percent on Wednesday.
Plug Power Inc (NASDAQ: PLUG) rose 8.9 percent to $2.45 in pre-market trading after surging 73.08 percent on Wednesday.
Coach Inc (NYSE: COH) rose 6.7 percent to $41.98 in pre-market trading. Coach named Ian Bickley as President, Global Business Development and Strategic Alliances.
Sapiens International Corporation N.V. (NASDAQ: SPNS) shares rose 6.1 percent to $13.91 in pre-market trading after gaining 0.54 percent on Wednesday.
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) rose 6.1 percent to $149.15 in pre-market trading. Jazz Pharma reached a settlement with Hikma Pharma related to Xyrem patent case. Mizuho downgraded Jazz from Buy to Neutral.
Interactive Brokers Group, Inc. (NASDAQ: IBKR) shares rose 6 percent to $36.72 in pre-market trading after declining 0.03 percent on Wednesday.
Rewalk Robotics Ltd (NASDAQ: RWLK) rose 5.3 percent to $2.00 in pre-market trading after the company disclosed that the U.S. Department of Veterans Affairs purchased 28 added Exoskeleton Systems.
Merrimack Pharmaceuticals Inc (NASDAQ: MACK) rose 5.1 percent to $3.29 in pre-market trading. Merrimack declared a $1.06 special dividend.
BioTime, Inc. (NYSE: BTX) shares rose 4.8 percent to $3.50 in pre-market trading. BioTime, reported the formation of new subsidiary AgeX Therapeutics, Inc.
Akari Therapeutics PLC (ADR) (NASDAQ: AKTX) shares rose 4.8 percent to $12.26 in pre-market trading after gaining 0.69 percent on Wednesday.
Bed Bath & Beyond Inc. (NASDAQ: BBBY) rose 3.6 percent to $39.15 in pre-market trading after the company posted better-than
- [By Ben Levisohn]
Jazz Pharmaceuticals (JAZZ) has jumped 6.3% to $149.45 after settling a patent dispute.
CarMax (KMX) gained 2.4% to $58 after beating earnings and sales forecasts.
Top 10 Warren Buffett Stocks To Invest In 2018: Black Diamond, Inc.(BDE)
- [By Jim Robertson]
At the beginning of the week, our Under the Radar Moversnewsletter suggested small cap sporting & outdoor goods stock Black Diamond Inc (NASDAQ: BDE) as a short/bearish trade:
Top 10 Warren Buffett Stocks To Invest In 2018: TherapeuticsMD, Inc.(TXMD)
- [By WWW.THESTREET.COM]
On the show’s “Lightning Round” segment, Jim Cramer was bullish on Penn National Gaming (PENN) , KeyCorp (KEY) and TherapeuticsMD (TXMD) .
- [By ]
TherapeuticsMD (Nasdaq: TXMD) is a pharmaceutical company with an exclusive focus on products for women and advanced hormone therapies. Biotech stocks are often a target for short sellers because of the uncertainty around drug development and approvals.
Top 10 Warren Buffett Stocks To Invest In 2018: State Bank Financial Corporation.(STBZ)
- [By Zacks]
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
J P Morgan Chase & Co (NYSE: JPM): Free Stock Analysis Report
Comerica Incorporated (NYSE: CMA): Free Stock Analysis Report
Wells Fargo & Company (NYSE: WFC): Free Stock Analysis Report
Citigroup Inc. (NYSE: C): Free Stock Analysis Report
Wintrust Financial Corporation (NASDAQ: WTFC): Free Stock Analysis Report
Synovus Financial Corp. (NYSE: SNV): Free Stock Analysis Report
State Bank Financial Corporation. (NASDAQ: STBZ): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Top 10 Warren Buffett Stocks To Invest In 2018: Aphria Inc. (APHQF)
- [By SEEKINGALPHA.COM]
When I began writing this, I had a 76% unrealized gain on my position in Aphria Inc (OTCQB:APHQF). It’s crunch time. This is where most sane individuals would be jumping ship and taking earnings. Me? I’m tempted to stay. Aphria has big things happening. The ramifications of the their developing marketplace in Canada are giving Aphria the potential to start reeling in some serious revenues. Furthermore, they have significant holdings in the United States that offer upside if regulatory hurdles don’t get in the way.
- [By Keith Speights]
As increasingly more marijuana growers entered the market and more states allowed residents to legally grow marijuana, cannabis prices dropped throughout 2016. Wholesale marijuana prices late in the year were roughly half the levels of 12 months earlier. Will this trend continue — and possibly hurt leading marijuana stocks including Aphria (NASDAQOTH:APHQF),Aurora Cannabis (NASDAQOTH:ACBFF), Medical Marijuana,Inc.(NASDAQOTH:MJNA), and even GW Pharmaceuticals (NASDAQ:GWPH) in the process?
- [By Sean Williams]
This rapid growth in legal pot has create quite the demand for marijuana stocks. The seven largest marijuana stocks by market cap have all put on a show over the past couple of years. Here are those seven “green giants” listed with their market caps as of March 17, 2017, along with their trailing one-year total returns.
GW Pharmaceuticals (NASDAQ:GWPH): $3.0 billion, up 64% Canopy Growth Corp. (NASDAQOTH:TWMJF): $904 million, up 259% Aphria (NASDAQOTH:APHQF) $440 million, up 381% Aurora Cannabis (NASDAQOTH:ACBFF): $482 million, up 299% AXIM Biotechnologies (NASDAQOTH:AXIM): $562 million, up 1,720% Corbus Pharmaceuticals (NASDAQ:CRBP): $450 million, up 431% Medical Marijuana (NASDAQOTH:MJNA): $221 million, up 254%
As you can see, these are some hefty valuations — and some exceptionally strong moves higher on the heels of marijuana’s expansion. With the exception of GW Pharmaceuticals, every one of the largest marijuana stocks has at least tripled in value over the trailing 12 months, with cannabinoid-based drug developer AXIM Biotechnologies skyrocketing more than 1,700%!
- [By SEEKINGALPHA.COM]
Aphria (OTCQB:APHQF) just did something very unusual and frankly caught us by surprise. The company announced that it is amending its previously announced transaction with Nuuvera (OTC:NUUVF) by which the cash portion of the consideration will be lowered from $1.00 to $0.60. The announcement surprised us as our past experience suggested that lowering purchase price post-deal announcement is extremely uncommon, especially in the absence of major negative developments at the target. Simultaneously, Nuuvera announced that it is acquiring the remaining 49% minority interest in Avanti Rx Analytics from a minority shareholder for $43 million. Avanti is a subsidiary of Nuuvera that provides research and testing services for cannabis companies. Nuuvera claimed that the reduced cash offer helps fund its acquisition, which makes no sense for us.
- [By Javier Hasse]
Also quite recently, Benzinga asked Alan Brochstein, founding partner at New Cannabis Ventures and founder at 420 Investor, about plays in the marijuana industry against such an uncertain backdrop. The expert mentioned a few Canadian Licensed Producers, including AURORA CANNABIS IN COM NPV (OTC: ACBFF), APHRIA INC NPV (OTC: APHQF), METTRUM HEALTH COR COM NPV (OTC: MQTRF), ORGANIGRAM HLDGS I COM NPV (OTC: OGRMF), SUPREME PHARMACEUT COM NPV (OTC: SPRWF) and CANOPY GROWTH CORP COM NPV (OTC: TWMJF), as well as “the only” biotech stock in the space, GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH).
Top 10 Warren Buffett Stocks To Invest In 2018: Mitel Networks Corporation(MITL)
- [By Lisa Levin]
ShoreTel Inc (NASDAQ: SHOR) shares shot up 28 percent to $7.47. Mitel Networks Corp (NASDAQ: MITL) announced plans to acquire Shortel for $7.50 per share in cash.
Top 10 Warren Buffett Stocks To Invest In 2018: PetroChina Company Limited(PTR)
- [By Money Morning News Team]
PetroChina Co. Ltd. (NYSE ADR: PTR) is China’s largest oil company with a market cap of $216.52 billion. PTR is partially owned by the Chinese government.